Answers are grounded in this paper and cite their sources.
Spinal cord injury (SCI) is a devastating condition that results in permanent functional impairments and poses a significant global health burden. Current treatment strategies primarily focus on mitigating secondary damage and rehabilitation, but they fail to address the regeneration of neural tissues. Glial cell line-derived neurotrophic factor (GDNF) has emerged as a promising therapeutic candidate due to its neuroprotective properties, including promoting neuronal survival, axonal regeneration, and reducing inflammation. This review summarizes the role of GDNF in SCI recovery, detailing its distribution and potential as a therapeutic agent. GDNF provides nutritional support to spinal neurons and enhances neuroplasticity following mechanical or ischemic injuries. Its combination with cell transplantation, gene therapy and biomaterial has shown synergistic effects in preclinical studies, offering potential strategies for neural repair and functional recovery. However, challenges such as effective delivery, safety concerns, and the heterogeneity of SCI necessitate further investigation. Advancing interdisciplinary approaches may unlock GDNF's clinical potential, paving the way for novel therapies targeting SCI.
No takes yet. Share an insight, caveat, or question.
Y. Zhao (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: